Brief: SK Bioscience Receives WHO Prequalification For Typhoid Conjugate Vaccine
23/02/2024 14:22
Feb 23 (Reuters) - SK Bioscience Co Ltd 302440.KS :
* SK BIOSCIENCE RECEIVES WHO PREQUALIFICATION FOR TYPHOID
CONJUGATE VACCINE
* SK BIOSCIENCE CO LTD- PLANS TO TARGET GLOBAL MARKETS WITH
SKYTYPHOID BY SEEKING APPROVALS IN VARIOUS COUNTRIES
* SK BIOSCIENCE CO LTD- OBTAINED PREQUALIFICATION
CERTIFICATION
FROM WORLD HEALTH ORGANIZATION FOR ITS TYPHOID CONJUGATE VACCINE
SKYTYPHOID
Source text for Eikon: ID:nPn1xCt64a
Further company coverage: 302440.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine